Public company info - CANbridge Pharmaceuticals Inc. , 01228.HK

Input the stock code or the company name     Search  
 
 Profile   Information   Data   Financial Ratios   Profit Loss   Cash Flow   Balance   Earnings   Dividend 

CANbridge Pharmaceuticals Inc., 01228.HK - Profit Loss 2021-12 2020-12 2019-12 2014-12 2013-12 2012-12 2011-12 2010-12 2009-12 2008-12 2007-12 2006-12 2005-12
Turnover 31,161 12,032 1,469 421,127 773,302 119,466 49,550 53,677 16,800 65,940 709,331 489,325 515,877
Operating Profit -1,039,814 -837,402 -217,675 -989,279 -265,217 -149,696 -661,232 81,571 683,220 -792,924 1,226,497 -25,298 43,424
Exceptional Items 0 0 0 0 0 0 0 0 0 0 -11,338 0 0
Associates 0 0 0 0 0 0 0 0 0 0 0 0 0
Profit Before Taxation -1,077,006 -846,043 -217,675 -989,279 -265,217 -149,696 -661,232 81,571 683,220 -792,924 1,215,159 -25,298 43,424
Taxation 0 0 0 -74,702 0 0 0 19 0 1,759 4,586 1,069 3,749
Minority Interests 0 0 0 -121,515 -3,340 -17,320 -2,947 0 78,132 -241,763 92,736 0 0
Net Profit -1,077,006 -846,043 -217,675 -793,062 -261,877 -132,376 -658,285 74,461 586,449 -639,881 1,117,837 -26,367 39,675
Currency Renminbi Renminbi Renminbi Hong Kong Dollar Hong Kong Dollar Hong Kong Dollar Hong Kong Dollar Hong Kong Dollar Hong Kong Dollar Hong Kong Dollar Hong Kong Dollar Hong Kong Dollar Hong Kong Dollar
Unit Thousand Thousand Thousand Thousand Thousand
Major Items
Depreciation 15,706 17,839 3,595 106,481 533 2,881 4,305 1,608 2,094 38,384 24,934 20,830 18,490
Interest Paid 3,079 3,794 1,349 8,962 0 1,591 450 1,192 14,263 38,538 11,338 4,419 2,609
Interest Capitalized 0 0 0 0 0 0 0 0 0 0 0 0 0
Non-current Assets Revaluation / Disposal 0 0 0 0 0 0 0 0 0 0 0 0 0
Taxation Rate (%) 7.55 0.02 0.31 0.38 8.63
Turnover Growth (%) 158.98 719.06 0.0 -45.54 547.3 141.1 -7.69 -87.55 -14.49 -28.92 44.96 -5.15 5.98
Net Profit Growth (%) -27.3 -288.67 0.0 -202.84 -97.83 79.89 0.0 -87.3 -59.82
Auditor's Opinion 1 0 0 1 1 1 1 1 1 2 1 1 1

Notes:1–Unqualified; 2–Unqualified ( not qualified in respect of fundamental uncertainly because of proper disclosure); 3–Qualified

 

88iv | Home |  Login
Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer
Copyright (C) 2024
Suntek Computer Systems Limited.
All rights reserved